Bloomberg Law
LinkedIn

AstraZeneca Awarded $855M Modification From DoD for Covid Pill

Feb. 11, 2022, 10:32 PM UTC
Sebastian Tong
Sebastian Tong
Bloomberg News

AstraZeneca Pharmaceuticals LP has been awarded a $855m modification for the manufacture, distribution and storage of its Covid-19 prevention pill Evusheld, the U.S. Department of Defense says in a statement.

  • Work to be performed in various locations, with an estimated completion date of March 31, 2023
  • NOTE: AstraZeneca Sees Sales and Profit Gaining on New Blockbusters

To contact the reporter on this story:
Sebastian Tong in San Francisco at stong41@bloomberg.net

To contact the editor responsible for this story:
Angela Moon at hmoon43@bloomberg.net

© 2022 Bloomberg L.P. All rights reserved. Used with permission.

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.